Cyramza® (Ramucirumab)

Para consultar la información para prescribir completa de Cyramza® (Ramucirumab) de clic en el siguiente enlace: Información para prescribir

La información es proporcionada en respuesta a su solicitud, y puede contener datos relacionados a dosis, usos, formulaciones y poblaciones diferentes a la Información para Prescribir del producto. Consulte la Información para Prescribir en la liga que aparece arriba.

Ramucirumab: Use in Elderly Patients in the REVEL Study

Among patients who received ramucirumab for NSCLC in the REVEL trial, the HR for median OS in patients ≥65 years was 1.10 (95% CI: 0.89-1.36).

MX_cFAQ_RAM070_REVEL_ELDERLY
MX_cFAQ_RAM070_REVEL_ELDERLY
es-MX

Study Design

The REVEL trial was a phase 3, multicenter, randomized, double-blind, placebo-controlled trial in patients with pathologically confirmed, squamous or nonsquamous, stage IV NSCLC with disease progression during or after 1 prior platinum-based chemotherapy. Prior treatment with bevacizumab and prior maintenance therapy were allowed and all patients had an ECOG PS of 0 or 1. Patients were randomly assigned in a 1:1 ratio (stratified by sex, region, PS, and previous maintenance therapy) to receive treatment with ramucirumab (10 mg/kg every 3 weeks) plus docetaxel (75 mg/m2 every 3 weeks) (n=628) or placebo plus docetaxel (75 mg/m2 every 3 weeks) (n=625) until disease progression, unacceptable toxicity, withdrawal, or death.1

Age was not a stratification factor in the REVEL study. Compared with the placebo plus docetaxel arm, more patients in the ramucirumab plus docetaxel arm were ≥65 years old (37.7% vs 34.9%, respectively).2

Efficacy

The OS results among elderly patients in the REVEL study are presented in Overall Survival Results According to Age of 65 Years and Overall Survival Results According to Age of 70 Years.

Overall Survival Results According to Age of 65 Years2

RAM + DOC
(n=237)

PBO + DOC
(n=218)

RAM + DOC
(n=391)

PBO + DOC
(n=407)

Age ≥65 Year

Age <65 Year

Median OS, mo (95% CI)

9.20 (7.62-10.32)

9.26 (8.54-10.97)

11.33 (10.28-12.55)

8.90 (7.36-10.18)

HR (95% CI)

1.10 (0.89-1.36); p=.393

0.74 (0.62-0.87); p<.001

Interaction p valuea

p=.004

Abbreviations: DOC = docetaxel; HR = hazard ratio; OS = overall survival; PBO = placebo; RAM = ramucirumab.

aP value for interaction term from a model with arm, the subgroup variable, and arm × subgroup interaction term.

Overall Survival Results According to Age of 70 Years2


RAM + DOC

(n=127)

PBO + DOC

(n=125)

RAM + DOC

(n=501)

PBO + DOC

(n=500)

Age >70 Year

Age <70 Year

Median OS, mo (95% CI)

8.84 (6.64-10.55)

9.00 (7.43-10.97)

10.94 (9.95-11.86)

9.13 (8.05-10.02)

HR (95% CI)

1.07 (0.80-1.43); p=.662

0.81 (0.70-0.94); p=.006

Interaction p valuea

p=.106

Abbreviations: DOC = docetaxel; HR = hazard ratio; OS = overall survival; PBO = placebo; RAM = ramucirumab.

aP value for interaction term from a model with arm, the subgroup variable, and arm × subgroup interaction term.

Safety

No clinically relevant differences were observed in terms of adverse event profile between treatment arms according to age 2. Treatment-emergent adverse events divided by age group that occurred in at least 20% of patients in the ramucirumab plus docetaxel arm are summarized in Treatment-Emergent Adverse Events in ≥20% of Patients Aged <65 Years or ≥65 Years.

Treatment-Emergent Adverse Events in ≥20% of Patients Aged <65 Years or ≥65 Years2

Adverse Event Term 

RAM + DOC
(n=237)
% of Patients

PBO + DOC
(n=214)
% of Patients

RAM + DOC
(n=390)
% of Patients

PBO + DOC
(n=404)
% of Patients

Age ≥65 Years

Age <65 Years

Fatiguea

58.2

56.5

52.6

46.5

Neutropeniaa

54.4

52.8

55.4

42.3

Neuropathya

19.4

22.0

25.4

19.6

Leukopeniaa

20.3

18.2

22.1

19.3

Anemiaa

24.5

30.4

18.7

27.0

Diarrhea

34.2

28.0

30.3

27.5

Nausea

30.0

29.4

25.1

26.5

Decreased appetite

32.9

33.2

26.7

20.5

Alopecia

26.6

25.2

25.4

25.2

Stomatitis

24.9

14.0

22.3

12.4

Dyspnea

25.7

24.3

19.7

24.0

Cough

19.8

15.9

22.1

23.3

Epistaxis

15.2

8.4

20.5

5.4

Abbreviations: DOC = docetaxel; MedDRA = Medical Dictionary for Regulatory Activities; PBO = placebo; RAM = ramucirumab.

aConsolidated term, based on MedDRA version 16.1.

References

1Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665-673. http://dx.doi.org/10.1016/S0140-6736(14)60845-X

2Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Glossary

ECOG = Eastern Cooperative Oncology Group

HR = hazard ratio

NSCLC = non-small cell lung cancer

OS = overall survival

PS = performance status

Fecha de la última revisión: 2019 M10 30


Contáctenos para saber más de la información Médica de Lilly

Contacto vía correo electrónico

Correo electrónico: infomed@lilly.com

Envíe su consulta

Escriba su consulta